307 related articles for article (PubMed ID: 27546465)
1. Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance.
Castillo JJ; Gertz MA
Leuk Lymphoma; 2017 Apr; 58(4):773-780. PubMed ID: 27546465
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia.
Tedeschi A; Conticello C; Rizzi R; Benevolo G; Laurenti L; Petrucci MT; Zaja F; Varettoni M
Hematol Oncol; 2019 Apr; 37(2):117-128. PubMed ID: 30192023
[TBL] [Abstract][Full Text] [Related]
3. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS).
Mailankody S; Pfeiffer RM; Kristinsson SY; Korde N; Bjorkholm M; Goldin LR; Turesson I; Landgren O
Blood; 2011 Oct; 118(15):4086-92. PubMed ID: 21795746
[TBL] [Abstract][Full Text] [Related]
4. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal gammopathy of undetermined significance.
Kyle RA
Blood Rev; 1994 Sep; 8(3):135-41. PubMed ID: 7819815
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA
Eur J Haematol Suppl; 1989; 51():70-5. PubMed ID: 2516809
[TBL] [Abstract][Full Text] [Related]
7. Waldenström macroglobulinaemia and IgM monoclonal gammopathy of undetermined significance: emerging understanding of a potential precursor condition.
McMaster ML; Caporaso N
Br J Haematol; 2007 Dec; 139(5):663-71. PubMed ID: 18021080
[TBL] [Abstract][Full Text] [Related]
8. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
[TBL] [Abstract][Full Text] [Related]
9. [Epidemiology of monoclonal gammopathies].
Hurez D
Rev Prat; 1993 Feb; 43(3):271-4. PubMed ID: 8502953
[TBL] [Abstract][Full Text] [Related]
10. Familial Waldenström Macroglobulinemia: Families Informing Populations.
McMaster ML
Hematol Oncol Clin North Am; 2018 Oct; 32(5):787-809. PubMed ID: 30190018
[TBL] [Abstract][Full Text] [Related]
11. Emerging concepts in monoclonal gammopathy of undetermined significance.
Freytes CO
Bol Asoc Med P R; 2010; 102(4):43-6. PubMed ID: 21766546
[TBL] [Abstract][Full Text] [Related]
12. Associated cancers in Waldenström macroglobulinemia: clues for common genetic predisposition.
Morra E; Varettoni M; Tedeschi A; Arcaini L; Ricci F; Pascutto C; Rattotti S; Vismara E; Paris L; Cazzola M
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):700-3. PubMed ID: 24070824
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
Correa JG; Cibeira MT; Tovar N; Isola I; Pedrosa F; Díaz T; Lozano E; Magnano L; Rosiñol L; Bladé J; Fernández de Larrea C
Br J Haematol; 2017 Dec; 179(5):849-851. PubMed ID: 27605200
[No Abstract] [Full Text] [Related]
14. Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.
Mailankody S; Landgren O
Best Pract Res Clin Haematol; 2016 Jun; 29(2):187-193. PubMed ID: 27825465
[TBL] [Abstract][Full Text] [Related]
15. Survival in monoclonal gammopathy of undetermined significance and Waldenström macroglobulinemia.
Kristinsson SY; Björkholm M; Landgren O
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):187-90. PubMed ID: 23490991
[TBL] [Abstract][Full Text] [Related]
16. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma.
Wadhera RK; Kyle RA; Larson DR; Dispenzieri A; Kumar S; Lazarus HM; Rajkumar SV
Blood; 2011 Sep; 118(11):2985-7. PubMed ID: 21765020
[TBL] [Abstract][Full Text] [Related]
17. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.
Go RS; Gundrum JD; Neuner JM
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):177-186.e4. PubMed ID: 25445471
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal gammopathy in Iceland: a population-based registry and follow-up.
Ogmundsdóttir HM; Haraldsdóttir V; M Jóhannesson G; Olafsdóttir G; Bjarnadóttir K; Sigvaldason H; Tulinius H
Br J Haematol; 2002 Jul; 118(1):166-73. PubMed ID: 12100144
[TBL] [Abstract][Full Text] [Related]
19. [Monoclonal gammopathy of undetermined significance--potential risk factor of multiple myeloma].
Stelmach-Gołdyś A; Czarkowska-Paczek B
Przegl Lek; 2012; 69(5):194-6. PubMed ID: 23050415
[TBL] [Abstract][Full Text] [Related]
20. Progression from Monoclonal gammopathy of undetermined significance of the immunoglobulin M class (IgM-MGUS) to Waldenstrom Macroglobulinemia is associated with an alteration in lipid metabolism.
Jalali S; Shi J; Ahsan N; Wellik L; Serres M; Buko A; Paludo J; Kim H; Tang X; Yang ZZ; Novak A; Kyle R; Ansell S
Redox Biol; 2021 May; 41():101927. PubMed ID: 33690107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
